Pfizer completes ResApp purchase for over $115 million
Biopharmaceutical giant Pfizer has finalised its acquisition of ASX-listed digital health startup ResApp for A$179 million ($116 million), according to the University of Queensland.
Brisbane-based ResApp has developed a mobile app that analyses cough sounds and diagnoses respiratory diseases, including asthma, pneumonia, bronchiolitis, croup...
